Trend Aggregation Conservative ETF TACE
Set alert
As of Sep 22, 3:59 PM ET
- Open
- 25.59
- Prev close
- 25.59
- Mkt cap
- 16.01M
- Vol
- 5.79K
- Avg vol
- 11.09K
- EPS
- 0.00
- P/E
- 0.00
- Div yield
- 0.00%
More statistics
- Low
- 25.55
- High
- 25.60
- Forward P/E
- 0.00
- Beta
- 0.00
- Short ratio
- 0.00
- Dividend
- 0.00
- Ex-div date
- 50-d avg
- 25.67
- 200-d avg
- 25.53
News
1 week ago gurufocus.com
IMFINZI® (durvalumab) plus tarlatamab-dlle reduced the risk of death by 58% in 1st-line extensive-stage small cell lung cancer in the DeLLphi-305 Phase III trial
Landmark results from the DeLLphi-305 Phase III trial showed IMFINZIÂ (durvalumab) plus Amgen's tarlatamab-dlle demonstrated a statistically significant and hi
1 week ago gurufocus.com
Perioperative IMFINZI® (durvalumab) plus neoadjuvant enfortumab vedotin reduced risk of recurrence by 49% and risk of death by 42% in muscle-invasive bladder cancer
Positive results from the VOLGA Phase III trial showed perioperative treatment with AstraZeneca's IMFINZIÂ (durvalumab) in combination with neoadjuvant enfortu
3 weeks ago defenseworld.net
Trend Aggregation Conservative ETF (NYSEARCA:TACE) Stock Price Down 0.2% – Time to Sell?
Trend Aggregation Conservative ETF (NYSEARCA:TACE - Get Free Report)'s share price fell 0.2% during mid-day trading on Friday. The company traded as low as $25.55 and last traded at $25.59.…
5 months ago businesswire.com
IMFINZI® (durvalumab) plus IMJUDO® (tremelimumab-actl) combined with lenvatinib and TACE reduced the risk of disease progression or death by 30% in embolization-eligible unresectable liver cancer in EMERALD-3 Phase III trial
WILMINGTON, Del.--(BUSINESS WIRE)--Positive results from the EMERALD-3 Phase III trial showed AstraZeneca's IMFINZI® (durvalumab) in combination with IMJUDO® (tremelimumab-actl), lenvatinib and…
5 months ago gurufocus.com
Hengrui Pharma Presents More Than 90 Oncology Studies at ASCO 2026, Highlighting Progress Across Multiple Tumor Types
Hengrui Pharma Presents More Than 90 Oncology Studies at ASCO 2026, Highlighting Progress Across Multiple Tumor Types PR Newswi
5 months ago gurufocus.com
IMFINZI® (durvalumab) approved in the US in first and only immunotherapy combination for patients with BCG-naïve, high-risk non-muscle-invasive bladder cancer
AstraZeneca's IMFINZIÂ (durvalumab) in combination with Bacillus Calmette-GuÃrin (BCG) induction and maintenance therapy has been approved in the US for the
9 months ago defenseworld.net
Trend Aggregation Conservative ETF (NYSEARCA:TACE) Shares Down 0.2% – Should You Sell?
Shares of Trend Aggregation Conservative ETF (NYSEARCA:TACE - Get Free Report) dropped 0.2% on Tuesday. The stock traded as low as $25.55 and last traded at $25.59. Approximately 5,700 shares were…
2 years ago businesswire.com
KEYTRUDA® (pembrolizumab) Plus LENVIMA® (lenvatinib) in Combination With Transarterial Chemoembolization Significantly Improved Progression-Free Survival Compared to TACE Alone in Patients With Unresectable, Non-Metastatic Hepatocellular Carcinoma
RAHWAY, N.J. & NUTLEY, N.J.--(BUSINESS WIRE)---- $MRK #MRK--KEYTRUDA Plus LENVIMA in Combination With TACE Significantly Improved PFS Compared to TACE Alone in Patients With Unresectable,…
5 years ago etf.com
ETF Odds & Ends: 2 Closures Announced
Plus, a number of fund names have changed.
5 years ago etf.com
ETF Odds & Ends: Veterans Fund Closes
Plus, Direxion launches a leveraged clean energy ETF.